VectorBuilder Wins Two IMAPAC Awards, Cementing Leadership in Gene Therapy and CDMO Innovation

Audio By Carbonatix

CHICAGO--(BUSINESS WIRE)--Sep 30, 2025--

VectorBuilder, a global leader in the gene delivery space, has won two prestigious awards at the Asia-Pacific Cell and Gene Therapy Excellence Awards 2025 ( APCGTEA ) and the Asia-Pacific Biologics CDMO Excellence Awards 2025 ( APBCEA ), hosted by IMAPAC.

• Best Cell & Gene Therapy Supplier Award – AAV Vector Manufacturing
• Best Gene Therapy CDMO – Asia-Pacific

VectorBuilder pioneers cutting-edge innovation for AAV gene delivery, with a one-stop solution supporting programs from research to early discovery to clinical development. Its proprietary technology platforms have enabled robust production of tens of thousands of custom AAV vectors for researchers and drug developers worldwide. Leveraging its expansive suite of AAV preclinical services, including a comprehensive capsid evolution platform, biodistribution profiling, and the bespoke cliniVec TM consultation service, VectorBuilder empowers its partners to accelerate and streamline their cell and gene therapy development. The company’s innovative AAV IP portfolio features novel AAV capsids, miniVec TM and MuteFree TM AAV backbones, and novel promoters, positioning VectorBuilder at the forefront of next-generation AAV innovations.

Offering a variety of systems that meet diverse needs, VectorBuilder is a full-service CDMO offering end-to-end solutions from development to production, having developed extensive expertise in process and analytical development for the manufacturing of GMP-grade gene therapy vectors. Operating several state-of-the-art facilities, VectorBuilder has supported many customers with the GMP manufacturing of plasmid DNA, viral vectors, IVT RNA, and LNP encapsulation. The highly experienced team has successfully provided plasmids, lentiviral vectors, and AAV vectors for their customers’ IND and IIT studies in the US and Asia. These recognitions add to a growing list of accolades for VectorBuilder, including the Bio-Industrial Innovation of the Year Award from BioTech Breakthrough (November 2024) and the CDMO Leadership Award from Outsourced Pharma and Life Science Connect (May 2025). Together, these honors reinforce VectorBuilder’s impact on the global CGT industry.

“We are honored to receive two IMAPAC awards at the same time, affirming the value of our commitment to innovation,” said Dr. Bruce Lahn, founder and Chief Scientist of VectorBuilder. “We will continue to advance gene delivery technologies and collaborate globally to enable breakthrough therapies and contribute to better human health.”

For more information, please visit www.vectorbuilder.com.

About VectorBuilder

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development, and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities, and state-of-the-art GMP manufacturing facilities. With leading R&D and CDMO capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new innovative tools for life sciences research and genetic medicine.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250930786846/en/

CONTACT: Media Inquiries

Sarah Shkargi

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS SCIENCE RESEARCH

SOURCE: VectorBuilder

Copyright Business Wire 2025.

PUB: 09/30/2025 06:00 AM/DISC: 09/30/2025 05:59 AM

http://www.businesswire.com/news/home/20250930786846/en